Mission

To stimulate research and evaluation on issues related to medication adherence, treatment persistence, and implications for health outcomes.

Background

Medication non-adherence has a significant impact on patients’ morbidity and mortality. Behavioral interventions have been developed to improve medication adherence. Adherence research requires an understanding about the best methodology to conduct studies especially when assessing interventions. Adherence studies include various designs such as: randomized controlled clinical trials, observational, and quasi-experimental studies. The Medication Adherence and Persistence Special Interest Group will develop good research practice recommendations for the conduct of medication adherence and treatment persistence research studies and will provide insight, through systematic reviews of the medication adherence literature, on interventions that improve medication adherence.


Leadership



Chair-Elect

John Zeber, PhD

Associate Professor, Umass Amherst
Brattleboro, VT, United States

Chair

Priti Pednekar, MS, BS, PhD

Research Scientist, PRECISIONheor
Newark, CA, United States

Past Chair

Elizabeth Manias, RPh, RN, PhD

Research Professor, Deakin University
Kew, VIC, Australia

Working Groups:



Member Engagement


Co-Chair

Andrew Peterson, PharmD, BS, PhD

University of the Sciences in Philadelphia
Philadelphia, PA, United States

Key Project

Criteria for the value assessment for medication adherence-enhancing interventions (MAEI)
PROSPERO registration number CRD42021242934

Background and Objectives for Key Project

Medication non-adherence is prevalent across all clinical conditions causing major medical and economic challenges. Although several studies have demonstrated that medication adherence enhancing interventions (MAEIs) may improve outcomes, existing evidence on the effectiveness of MAEIs is of poor quality. Important policy decisions about MAEIs are currently based on inadequate information.

Evidence suggests that the number of economic evaluations investigating MAEIs is limited, and the overall quality of existing analyses is modest. Increased medication adherence is generally associated with increased effectiveness of the therapy but does not have a consistent relationship with costs.

This project aims to systematically identify relevant criteria for the value assessment of MAEIs by considering the perspectives of various types of stakeholders, including payers, healthcare providers, industry, academia and patients.

Co-Chairs:

Tamas Agh, MSc, PhD, MD

Principal Researcher, 1) Division of Pharamcoeconomics, University of Pecs 2) Syreon Research Institute
Budapest, PE, Hungary

Bijan Borah, MSc, PhD

Professor of Health Services Research, Mayo Clinic College of Medicine
Rochester, MN, United States

Mickaël Hiligsmann, PhD

Associate Professor, Maastricht University
Maastricht, LI, Netherlands

Questions or ideas? Please send an email.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×